ANI Pharmaceuticals EPS Forecast Rises 22.1% to $1.99 on $233M Sales
ANI Pharmaceuticals is forecast to report fourth-quarter EPS of $1.99, up 22.1% year over year, on revenues of $232.98 million, a 22.3% increase. Consensus EPS estimates have fallen 14.6% over the past 30 days, leaving a -1.81% Earnings ESP despite a factor-based rank of #2.
1. Q4 Earnings Estimates
ANI Pharmaceuticals is expected to report fourth-quarter EPS of $1.99, up 22.1% year over year, on revenues of $232.98 million, marking a 22.3% increase from the prior year period.
2. Estimate Revisions and Earnings ESP
Consensus EPS estimates for the quarter have been revised 14.6% lower over the past month, producing a -1.81% Earnings ESP and reflecting recent analyst bearishness despite the company’s factor-based rank of #2.
3. Historical Surprise Performance
The company has beaten consensus EPS estimates in each of the last four quarters, including a +17.24% surprise in the most recent period, underscoring its track record of surpassing analyst forecasts.